Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM

(TheNewswire)

Toronto, Ontario – TheNewswire - 5 September 2025 –Helix BioPharma Corp. (TSX:“HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company” ), aclinical-stage oncology company shaping a near future where today’shard-to-treat cancers are vincible, announced today that it haselected not to proceed with the previously announced equity draw-downsubscription facility with GEM Global Yield LLC SCS and GEM YieldBahamas Limited (together, “GEM” ).

The Company entered into a non-binding term sheet datedOctober 15, 2024 with GEM, and disclosed the proposed subscriptionfacility in news releases dated February 24, 2025 and March 26, 2025and in the Company’s Management and Information Circular datedJanuary 31, 2025. 1 The Companyreceived shareholder approval of the financing arrangement at theCompany’s annual general and special meeting on March 26, 2025. However, following a thorough evaluation of market conditions andlong-term corporate objectives, Helix determined that the GEM facilityno longer aligns with its capital strategy or its commitment tomaximizing long-term shareholder value.  The letter of intent expiredin accordance with its terms and the Company has elected not toproceed to execution of the binding agreements or pursue the financingwith GEM.

Independently of this decision, Helix continues toengage in constructive discussions with financial partners to explorealternative financing structures that may better align with theCompany’s needs and strategic direction. The Company remainssteadfast in its commitment to securing the capital required toadvance its clinical programs and achieve its corporate objectives.

About Helix BioPharma

Helix BioPharma is an oncology company that innovatesfrom strength to bring near-term solutions for today’shardest-to-treat cancers. The Company’s pipeline is led by TumorDefense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugatedesigned to prime CEACAM6-expressing tumors for increased sensitivityto therapy and augment the effectiveness of today’s front-runninganti-cancer treatments. L-DOS47 has completed Phase Ib studies innon-small cell lung cancer (NSCLC) and shares its CEACAM6-targetingfoundation with Helix’s next-generation bi-specific antibody-drugconjugates (ADCs), currently in discovery. The Company also advancestwo pre-IND candidates: (i) LEUMUNA™, an oral immune checkpointmodulator aimed at achieving durable remission in post-transplantleukemia relapse, and (ii) GEMCEDA™, a first-in-class oralgemcitabine prodrug with bioavailability on a par with IV, designed toexpand treatment options for advanced cancers.

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB(HBP0). For more information, pleasevisit : https://www.helixbiopharma.com/

For more information, pleasecontact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Thomas Mehrling, CEO

corporate@helixbiopharma.com

Forward-Looking Statements and Risksand Uncertainties

This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to Tumor DefenseBreaker™ L-DOS47, LEUMUNA™ and GEMCEDA™. Forward-lookingstatements can further be identified by the use of forward-lookingterminology such as “ongoing”, “estimates”, “expects”, orthe negative thereof or any other variations thereon or comparableterminology referring to future events or results, or that events orconditions “will”, “may”, “could”, or “should” occuror be achieved, or comparable terminology referring to future eventsor results.

Forward-looking statements arenecessarily based on a number of estimates and assumptions that theCompany considered appropriate and reasonable as of the date suchinformation is given, including but not limited to the assumptionsregarding the implied benefits of the transactions. Forward-lookingstatements are subject to known and unknown risks, uncertainties, andother factors, many of which are beyond the Company’s control, thatmay cause actual results, performance or achievements to be materiallydifferent from those expressed or implied by such forward-lookingstatements, including but not limited to the risk that theCompany's assumptions on which its forward-looking statements arebased may not be accurate; the ability of the Company to capitalize onthe potential benefits of the transactions; and the risk factorsdisclosed in the Company's periodic reports publicly filed andavailable on its SEDAR+ profile at www.sedarplus.ca . No assurance can be given that any ofthe events anticipated by the forward-looking statements willtranspire or occur. There is no assurance that the proposedtransactions will be completed in accordance with its terms or at all.The forward-looking statements contained in this news release are madeas of the date of this announcement and the Company does not assumeany obligation to update any forward-looking statement or informationshould those beliefs, assumptions, opinions or expectations, or othercircumstances change, except as required by law.

_________________

1 https://www.helixbiopharma.com/fy2025/helix-biopharma-corp-extends-date-of-annual-general-and-special-meeting-to-seek-approval-of-asset-acquisitions-and-proposed-financing/ ; https://www.helixbiopharma.com/fy2025/helix-biopharma-corp-announces-voting-results-from-its-annual-general-and-special-meeting/ ; https://www.helixbiopharma.com/wp-content/uploads/2025/03/Management-Information-Circular-31-January-2025.pdf .

Copyright (c) 2025 TheNewswire - All rights reserved.